TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9666415
Drug: Leflunomide 10
Normalized name: leflunomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 10 mg and 25 mg
Study: 2688186
Drug: HR capsules
Normalized name: Synovex H
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR capsules (1,200 mg/day)
Study: 12457672
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and retrobulbar anesthesia
Study: 3901934
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (high sodium isotonic fluid at 40 ml/kg per hour during rehydration phase, low sodium isotonic fluid during maintenance phase)
Study: 31699150
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg, p.o. q.d.) plus gefitinib (250 mg, p.o. q.d.)
Study: 17671066
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray (5 mg)
Study: 15616064
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate 0.1 mg.kg(‐1).min(‐1)
Study: 1080266
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg methylergonovine maleate (Methergine) intramuscularly
Study: 31068125
Drug: Message 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Message 2 (depression needs treatment)
Study: 31068125
Drug: Message 3
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Message 3 (depression improves with treatment)
Study: 19381735
Drug: Probiotics (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2.4 billion colonies of Lactobacillus administered daily postoperatively)
Study: 14679122
Drug: Irinotecan (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) with 5‐fluorouracil (400 mg/m² bolus) and leucovorin (125 mg/m²) followed by 5‐FU (1200 mg/m² infusion over 48 h) every 2 weeks
Study: 14679122
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and 5‐fluorouracil treatment
Study: 7699621
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) treatment
Study: 7950184
Drug: Kuiyangqing Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuiyangqing Pill (KYQP) for EHS group
Study: 7950184
Drug: Bismuth aluminate
Normalized name: BISMUTH ALUMINATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth aluminate tablets (control) for EHS group
Study: 7950184
Drug: Kuiyangqing Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuiyangqing Pill (KYQP) for DCS group
Study: 7950184
Drug: Bismuth aluminate
Normalized name: BISMUTH ALUMINATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth aluminate tablets (control) for DCS group
Study: 3109990
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rioprostil
Study: 24972907
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment programme (STP)
Study: 23296827
Drug: Tannin diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tannin diet (20 g DM of alfalfa hay/kg BW supplemented with 50 g of quebracho/kg DM)
Study: 23296827
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (20 g DM of alfalfa hay/kg BW)
Study: 21723792
Drug: Paclitaxel, Bevacizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, Bevacizumab, and Gemcitabine (PB+G)
Study: 17111014
Drug: Caffeine (CAFF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAFF; 5 mg/kg body mass)
Study: 15679253
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and its derivatives with radiation therapy
Study: 9485982
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg.kg‐1)
Study: 9485982
Drug: Morphine (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.09 mg.kg‐1)
Study: 3540140
Drug: Aminoglycoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside therapy (gentamicin, tobramycin, amikacin)
Study: 29030199
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg iodine orally once a day until delivery
Study: 26319820
Drug: Low-fat, phytosterol-supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, phytosterol-supplemented milk (2.24 gr of plant sterols daily)
Study: 23810643
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of beer
Study: 23810643
Drug: 800 mL
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mL of dealcoholized beer
Study: 23810643
Drug: 67 mL
Normalized name: ethanol 0.67 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67 mL of vodka and 733 mL water
Study: 18826157
Drug: Shen Shuai
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen Shuai Fang + western medicine
Study: 10868311
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) interferon alfa‐n3 (10 million units)
Study: 10868311
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) interferon alfa‐n3 (10 million units)
Study: 10868311
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) interferon alfa‐n3 (10 million units)
Study: 1417314
Drug: Endolymphatic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endolymphatic administration of kanamycin
Study: 1417314
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of kanamycin
Study: 1417314
Drug: Lymphotropic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lymphotropic administration of kanamycin
Study: 1417314
Drug: Endolymphatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic therapy during postoperative period
Study: 6519841
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg, four times a day for 3 weeks
Study: 6519841
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg, four times a day for 3 weeks
Study: 30383495
Drug: IDegLira (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegLira (insulin degludec/liraglutide)
Study: 26093599
Drug: Dehydroepiandrosterone (DHEA)
Normalized name: DEHYDROEPIANDROSTERONE (DHEA) CAP/TAB
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydroepiandrosterone (DHEA) 100 mg
Study: 15054445
Drug: Haematopoietic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haematopoietic growth factors (HGF) plus chemotherapy
Study: 9626025
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 micrograms once daily
Study: 9626025
Drug: Formoterol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 6 micrograms twice daily
Study: 9626025
Drug: Terbutaline 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 500 micrograms four times daily
Study: 26718065
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous cannulae (PIVC) inserted
Study: 23941313
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for depression
Study: 21075578
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and ultra-low-dose naltrexone
Study: 21075578
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (with placebo)
Study: 20207004
Drug: Parenting skills
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting skills training (2-hour weekly sessions for 2 weeks)
Study: 15816462
Drug: Methylprednisolone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (500 mg/body) in saline 2 hours before surgery
Study: 12166555
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg) and Loratadine (10 mg)
Study: 8092839
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily for 14 days
Study: 8092839
Drug: Trimethoprim-sulfamethoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days
Study: 3041830
Drug: Intramuscular cefamandole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cefamandole
Study: 27999758
Drug: GPC3 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPC3 peptide vaccine
Study: 1442957
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (1 mg/day orally)
Study: 22570949
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg every 12 hours for 3 months)
Study: 19952722
Drug: Supplemental protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental protective drug (thiopental or etomidate), n = 178
Study: 17609936
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (diclofenac 50 mg)
Study: 16197471
Drug: Oral suplatast
Normalized name: Suplatast
DrugBank: Suplatast (DB19138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suplatast 300 mg daily for 3 months
Study: 12377628
Drug: Domestically manufactured
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestically manufactured low-molecular-weight heparin
Study: 12377628
Drug: Imported low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported low-molecular-weight heparin
Study: 1358620
Drug: Ebastine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine (20 mg)
Study: 7752640
Drug: Alcohol (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.35 g/kg)
Study: 2271194
Drug: Droperidol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (both doses)
Study: 30985632
Drug: Single 900-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 900-mg oral dose of delafloxacin
Study: 30985632
Drug: Single 250-mg
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 250-mg intramuscular ceftriaxone
Study: 16399173
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg for 5 days
Study: 16399173
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg for 10 days
Study: 9006374
Drug: Fluorouracil/epinephrine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil/epinephrine gel
Study: 9006374
Drug: Fluorouracil gel
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil gel alone
Study: 8433075
Drug: Dietary fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary fructose (20% of carbohydrate calories, 45‐65 g day‐1 for 4 weeks)
Study: 2825941
Drug: Isoproterenol, terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol, terbutaline, and epinephrine (beta-agonists)
Study: 2825941
Drug: Beta 1‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1‐ and beta 2‐receptor stimulation
Study: 29846653
Drug: DHA (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (2.7 g/d)
Study: 22429693
Drug: Health Workshops
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Workshops (8 weekly sessions)
Study: 8653019
Drug: Solipid 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solipid 20% S&E (lipid emulsions based on soy oil with egg lecithin or soy lecithin) administered at 1 g/kg body weight on day 1 and 2 g/kg/day on days 2-5
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 2-4 mg/kg
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 5-6 mg/kg
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 3 mg/kg
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 6 mg/kg
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 3 mg/kg plus infusion of 0.6 mg kg‐1 h‐1
Study: 1455403
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) 5 mg/kg plus infusion of 1 mg kg‐1 h‐1
Study: 1455403
Drug: Standard unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unfractionated heparin (UFH)
Study: 27856475
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (Control)
Study: 30212961
Drug: LED applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED applications (intra oral with 660 nm, 12J and extraoral with 850 nm, 108J)
Study: 25430452
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block with 0.2% ropivacaine at 5 ml/h
Study: 25430452
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block with 0.2% ropivacaine at 5 ml/h
Study: 22540635
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + NAC (100 mg/d clomiphene citrate + 1.2 g/d N-acetylcysteine)
Study: 22540635
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + Placebo (100 mg/d clomiphene citrate + placebo)
Study: 20630595
Drug: Anti-VEGF agent
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF agent (ranibizumab)
Study: 17599560
Drug: Oral corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroid treatment
Study: 8297690
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg twice daily)
Study: 8297690
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benazepril and nifedipine
Study: 2920133
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dihydrocodeine
Study: 4405419
Drug: Low-dose marijuana
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose marijuana (4.8 mg Delta(9)-THC followed by 2.4 mg one hour later)
Study: 4405419
Drug: High-dose marijuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose marijuana (9.1 mg Delta(9)-THC followed by 4.5 mg one hour later)
Study: 31200349
Drug: Supervised aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised aerobic and resistance exercise of moderate to vigorous intensity 3 times per week until the end of treatment, then twice per week for 10 weeks, followed by once per week for 10 weeks
Study: 25531162
Drug: GS-4997 (ASK1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-4997 (ASK1 inhibitor), once daily, oral administration
Study: 24101040
Drug: Dose-dense temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-dense temozolomide (arm 2) for 6 to 12 cycles
Study: 24101040
Drug: Dose-dense temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-dense temozolomide (arm 2)
Study: 12064924
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (calcitriol and enzyme therapy)
Study: 10458121
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent topical glyceryl trinitrate ointment
Study: 328139
Drug: Radiation alone
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation alone or in combination with chemotherapy
Study: 328139
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by immunotherapy
Study: 28924366
Drug: Dexmedetomidine in
Normalized name: dexmedetomidine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine in combination with fentanyl-based IV-PCA (dIV-PCA group)
Study: 21863672
Drug: AS03(A)‐adjuvanted H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)‐adjuvanted H5N1 influenza vaccine
Study: 21863672
Drug: Non‐adjuvanted H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐adjuvanted H5N1 vaccine formulations
Study: 9692166
Drug: albendazole (alb)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole (alb) 600 mg + ivermectin (iver) 400 micrograms/kg
Study: 9692166
Drug: albendazole (alb)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole (alb) 600 mg
Study: 9692166
Drug: albendazole (alb)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole (alb) 600 mg + diethylcarbamazine (DEC) 6 mg/kg
Study: 9692166
Drug: diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diethylcarbamazine (DEC) 6 mg/kg + ivermectin (iver) 400 micrograms/kg
Study: 7599511
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (45 mg daily for 60 days)
Study: 31721978
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor copayment reduction intervention (vouchers waiving copayments for 1 year)
Study: 23938046
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy
Study: 17171602
Drug: Family-Focused Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Focused Treatment
Study: 15103479
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure, maggot therapy, electromagnetic therapy, therapeutic ultrasound, growth factors
Study: 1288660
Drug: Low-dose levodopa,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose levodopa, bromocriptine, or a combination of both drugs
Study: 29373734
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment for 36 months
Study: 29373734
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 36 months
Study: 25080051
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (40 ppm)
Study: 25080051
Drug: Sham inhaled
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham inhaled nitric oxide administration
Study: 20673983
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - Budesonide
Study: 8873389
Drug: 23‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23‐valent pneumococcal polysaccharide vaccine
Study: 15641062
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (methotrexate + etanercept)
Study: 15641062
Drug: Monotherapy (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (methotrexate or etanercept)
Study: 11465011
Drug: Individual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual and group psychotherapy, cognitive-behavioral therapy, 12-step programmes
Study: 11465011
Drug: Serotonin (5-hydroxytryptamine;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin (5-hydroxytryptamine; 5-HT) re-uptake inhibitors
Study: 9459044
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg enteric-coated tablet
Study: 9459044
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg capsule
Study: 3306891
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ASA and 1 g sucralfate four times daily
Study: 3306891
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ASA four times daily and placebo tablets
Study: 3306891
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs administered
Study: 26162632
Drug: Rituximab 1000mg
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000mg twice at 2 weeks interval
Study: 16868064
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (strict blood glucose control to normoglycemia with insulin)